SMARCB1 and neoplasm: The results of a clinical trial are exciting that EZH2 binding tazemetostat provides an anti-tumor immunoreaction via inducing multiple T cell populations to infiltrate tumors and demonstrates the potential effect on the epigenetic regulation of immunoreaction in SMARCB1/INI1-negative PDC and this patient also has a benefit in OS [41].